| Name | Title | Contact Details |
|---|
The Macroflux Corp. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. Our client-first passion elevates, accelerates, and amplifies commercial success from product to patient.
Cardioxyl Pharmaceuticals is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US WorldMeds is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.